The Indian Patent Office has rejected Viiv Healthcare’s patent application for the HIV drug, dolutegravir, after nearly a decade of legal battles. This decision opens the market for generic versions, promoting affordable access to treatment and potentially reducing costs. The ruling addresses concerns over ‘evergreening’ practices in patent filings.
Patent for HIV drug rejected, paves way for entry of generics
Categories:
Related Post
‘Remorseless, psychopath’: How a class 12 student killed his school principal‘Remorseless, psychopath’: How a class 12 student killed his school principal
A 17-year-old student in Madhya Pradesh, India, fatally shot his school principal, Surendra Kumar Saxena, after being reprimanded for his behavior. The student, described by police as remorseless and possibly
Democratic governors push back against TrumpDemocratic governors push back against Trump
With Democrats in the minority in Washington, D.C., it could be up to governors to mount the party’s opposition to President Trump’s agenda. Ofirah Yheskel, director of external affairs for
In just 2 hours, this tiny smart home can be set up nearly anyplaceIn just 2 hours, this tiny smart home can be set up nearly anyplace
We’ve reported on a fair number of tiny homes in the past, but this one takes things to a whole new level. It’s called the Massimo Modular E9. At just